Swiss and French booster dose for Hyderabad cases | Hyderabad News

HYDERABAD: A month after opening its integrated R&D and manufacturing facility in Hyderabad’s Genome Valley with an investment of 30 million euros (about Rs 250 crore), Swiss biopharmaceutical giant Ferring Pharmaceuticals is now gearing up to inject Another €60 million (about Rs 250 crore). 500 crore) in expanding its facilities in Hyderabad over the next two to three years.

While the recently opened facility in Hyderabad was focused on the development and manufacturing of urology products based on its proprietary fast-dissolving granule (FDG) technology platform, the proposed unit will focus on the manufacturing of its gastro-drug – enterologic, Pentasa (mesalazine), which is used for the treatment and long-term management of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease.
The announcement was made by the Telangana government on Wednesday after State Industries Minister KT Rama Rao met with Ferring Executive Vice President and Chief Manufacturing and Supply Officer Alessandro Gilio as well as other members of Ferring’s management team, including François Hosotte, vice president of strategic projects and engineering.
Currently, Ferring has only one formulation unit for the production of Pentasa at its headquarters in St Prex, Switzerland, and the second unit will now be installed in Hyderabad under the umbrella of Ferring Laboratories Pvt Ltd. Pentasa is sold in oral form as tablets and granules. sachets.
Ferring, one of the world’s largest producers of mesalazine, currently manufactures Pentasa’s active pharmaceutical ingredient (API) mesalazine at two manufacturing facilities around the world, one in Denmark and one near mumbai.
The $2 billion turnover Ferring, headquartered in Saint-Prex, operates in reproductive medicine and maternal health, as well as specialist areas of gastroenterology and urology.


Comments are closed.